Minerva Outlines Next Steps For US Application For Schizophrenia Candidate
Minerva Neurosciences Inc (NASDAQ: NERV) received the
Watching Minerva Shares Following Circulation Of European Patent Specific For Co.’s ‘METHODS OF USE CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR-MEDIATED DISORDERS’
https://data.epo.org/publication-server/pdf-document?pn=2595485&ki=B1&cc=EP
HC Wainwright & Co. Maintains Buy on Minerva Neurosciences, Lowers Price Target to $5
HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:NERV) with a Buy and lowers the price target from $10 to $5.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Oncternal Therapeutics (NASDAQ:ONCT) shares moved upwards by 7.0% to $2.0 during Monday's after-market session. The company's market cap stands at $98.8 million.
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
